CA3253055A1 - Fusion proteins with extended half-life domains - Google Patents

Fusion proteins with extended half-life domains

Info

Publication number
CA3253055A1
CA3253055A1 CA3253055A CA3253055A CA3253055A1 CA 3253055 A1 CA3253055 A1 CA 3253055A1 CA 3253055 A CA3253055 A CA 3253055A CA 3253055 A CA3253055 A CA 3253055A CA 3253055 A1 CA3253055 A1 CA 3253055A1
Authority
CA
Canada
Prior art keywords
protein
seq
fusion protein
mutein
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3253055A
Other languages
English (en)
French (fr)
Inventor
Ulrich Haupts
Eva Bosse-Doenecke
Gregor HOFFMANN
Manja Gloser-Braeunig
Original Assignee
Navigo Proteins GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navigo Proteins GmbH filed Critical Navigo Proteins GmbH
Publication of CA3253055A1 publication Critical patent/CA3253055A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3253055A 2022-06-30 2023-06-30 Fusion proteins with extended half-life domains Pending CA3253055A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP22182401 2022-06-30
EP22182401.4 2022-06-30
EP22205669 2022-11-04
EP22205669.9 2022-11-04
PCT/EP2023/068109 WO2024003393A1 (en) 2022-06-30 2023-06-30 Fusion proteins with half life extending domains

Publications (1)

Publication Number Publication Date
CA3253055A1 true CA3253055A1 (en) 2024-01-04

Family

ID=87136437

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3253055A Pending CA3253055A1 (en) 2022-06-30 2023-06-30 Fusion proteins with extended half-life domains

Country Status (7)

Country Link
US (1) US20250388696A1 (enExample)
EP (1) EP4547708A1 (enExample)
JP (1) JP2025525305A (enExample)
CN (1) CN119487061A (enExample)
AU (1) AU2023301542B2 (enExample)
CA (1) CA3253055A1 (enExample)
WO (1) WO2024003393A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024401183A1 (en) * 2023-12-12 2026-04-30 Navigo Proteins Gmbh Novel serum albumin-binding fusion proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013148966A1 (en) * 2012-03-28 2013-10-03 Amylin Pharmaceuticals, Llc Transmucosal delivery of engineered polypeptides
WO2019091918A1 (en) * 2017-11-07 2019-05-16 Navigo Proteins Gmbh Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
CA3139164A1 (en) * 2019-06-04 2020-12-10 Molecular Partners Ag Recombinant fap binding proteins and their use
CA3184995A1 (en) * 2020-07-16 2022-01-20 Navigo Proteins Gmbh Serum stable binding proteins for human her2 for theranostic applications

Also Published As

Publication number Publication date
AU2023301542B2 (en) 2026-06-11
JP2025525305A (ja) 2025-08-05
EP4547708A1 (en) 2025-05-07
AU2023301542A1 (en) 2025-01-02
US20250388696A1 (en) 2025-12-25
WO2024003393A1 (en) 2024-01-04
CN119487061A (zh) 2025-02-18

Similar Documents

Publication Publication Date Title
US12611441B2 (en) PSMA specific binding proteins for cancer diagnosis and treatment
AU2019409572B2 (en) Novel FOLR1 specific binding proteins for cancer diagnosis and treatment
US20250388696A1 (en) Fusion proteins with half life extending domains
JP2026031936A (ja) 線維芽細胞活性化タンパク質（ｆａｐ）のための特異的結合性分子
AU2024401183A1 (en) Novel serum albumin-binding fusion proteins
EP4161954B1 (en) Serum stable binding proteins for human her2 for theranostic applications
AU2023366220B2 (en) Novel proteins with high binding affinity to programmed death ligand 1 (pd-l1)
WO2026022338A1 (en) Specific binding proteins for human erb-b3 receptor tyrosine kinase 3 (her3)
CN118317972A (zh) 成纤维细胞活化蛋白（fap）的特异性结合分子

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20241111

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250206

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250206

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250206

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250218

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260622

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260622